Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – X-ray contrast imaging agent
Reexamination Certificate
2005-12-13
2005-12-13
Jones, Dameron L. (Department: 1616)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
X-ray contrast imaging agent
C424S001110, C424S001650, C424S009420, C424S009100, C424S001810, C424S001850, C424S001890
Reexamination Certificate
active
06974567
ABSTRACT:
Detectably labeled macrophage scavenger receptor antagonists useful for the diagnosis and monitoring of various cardiovascular diseases including but not limited to atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
REFERENCES:
patent: 4577042 (1986-03-01), Collins et al.
patent: 4678667 (1987-07-01), Meares et al.
patent: 4752141 (1988-06-01), Sun et al.
patent: 4885363 (1989-12-01), Tweedle et al.
patent: 4923985 (1990-05-01), Gansow et al.
patent: 4986671 (1991-01-01), Sun et al.
patent: 5053053 (1991-10-01), DeLabbey et al.
patent: 5087440 (1992-02-01), Cacheris et al.
patent: 5155215 (1992-10-01), Ranney
patent: 5275594 (1994-01-01), Baker et al.
patent: 5310535 (1994-05-01), Kruper, Jr. et al.
patent: 5428154 (1995-06-01), Gansow et al.
patent: 5428156 (1995-06-01), Mease et al.
patent: 5739323 (1998-04-01), Kruper, Jr. et al.
patent: 5744120 (1998-04-01), Edwards et al.
patent: 5756065 (1998-05-01), Wilson et al.
patent: 5846519 (1998-12-01), Tweedle et al.
patent: 5879659 (1999-03-01), Edwards et al.
patent: 5958374 (1999-09-01), Meares et al.
patent: 6010679 (2000-01-01), Edwards et al.
patent: B-35519 (1993-09-01), None
patent: 0 292 689 (1988-11-01), None
patent: 0 382 583 (1990-08-01), None
patent: 0 565 930 (1993-10-01), None
patent: WO 87/05030 (1987-08-01), None
patent: WO 89/01476 (1989-02-01), None
patent: WO 90/12050 (1990-10-01), None
patent: WO 91/14458 (1991-10-01), None
patent: WO 93/06868 (1993-04-01), None
patent: WO 95/26206 (1995-10-01), None
patent: WO 97/32862 (1997-09-01), None
patent: WO 98/11475 (1998-03-01), None
patent: WO 98/53858 (1998-12-01), None
patent: WO 99/07382 (1999-02-01), None
patent: WO 99/67284 (1999-12-01), None
patent: WO 00/03704 (2000-01-01), None
patent: WO 00/06147 (2000-02-01), None
Agatson, A.S., et al., “Quantification of coronary artery calcium using ultrafast computed tomography,”J. Am. Coll. Cardiol., Mar. 15, 1990, 15(4), 827-832.
Alderman, E.L., et al., “Five-yar angiographic follow-up of factors associated with progression of coronary artery disease in the coronary artery surgery study (CASS),”J. Am. Coll. Cardiol., Oct. 1993, 22(4), 1141-1154.
Ambrose, J.A., et al., “Angiographic progression of coronary artery disease and the development of myocardial infarction,”J. Am. Coll. Cardiol., Jul. 1988, 12(1), 56-62.
Ambrose, J.A., “ Angiographic correlations of advanced coronary lesions in acute coronary syndromes,”Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, Fuster, V. (Ed.),Futura Publishing Co., Inc., 1996, 105-122.
Anderson, C.J., et al., “Radiometal-labeled agents (non-technetium for diagnostic imaging,”Chem. Rev., 1999, 99(9), 2219-2234.
Anson, F.C., et al., “Interconversion of planar and nonplanar N-amido ligands. Thermodynamically stable nonplanar N-anudi kugabdsm”J. Am. Chem. Soc., 1996, 108(21), 6593-6605.
Antopolsky, M., et al., “Peptide-oligonucleotide phosphorothioate conjugates with membrane translocation and nuclear localization properties,”Bioconjugate Chem., 1999, 10, 598-606.
Atsma, D.E., et al., “Potential of99mTc-LDLs labeled by two different methods for scintigraphic detection of experimental atherosclerosis in rabbits,”Arteroscler and Thromb, Jan. 1993, 13(1), 78-83.
Barrington, S.F., “Clinical use of PET in neurology,”Nucl. Med. Commun., Mar. 2000, 21(3), 237-240.
Bar-Shalom, R., et al., “PET imaging in oncology,”Seminars in Nucl. Med., Jul. 2000, 30(3), 150-185.
Baumgartener, H.-R., et al., “Eine neue methode zur erzeugung von thrombin durch gezielte Überdehnung der gefäβwand,”Gesamte Exp. Med., 1963, 137, 227-249 (German).
Bayley, H., “Protein therapy—delivery guaranteed,”Nat. Biotechnol., Nov. 1999, 17(11), 1066-1067.
Becker, C.R., et al., “Visualization and quantification of coronary calcifications with electron beam and spiral computed tomogramphy,”Eur. Radiol., 2000, 10, 629-635.
Bhorde, R., et al., “Macrocyclic chelators with paramagnetic cations are internalized into mammalian cells via a HIV-Tat derived membrane translocation peptide,”Bioconjugate Chem., May/Jun. 2000, 11(3), 301-305.
Bousquet, J.-C., et al., “Characterization of a new paramagnetic complex1,”Radiology, Mar. 1988, 166(3), 693-698.
Brechbiel, M.W., et al., “Backbone-substituted DTPA ligands for90Y radioimmunotherapy,”Bioconjugate Chem., 1991, 2, 187-194.
Brechbiel, M.W., et al., “synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA, antibody labeling and tumor-imaging studies,”Inorg. Chem., 1987, 25, 2772-2781.
Brundage, B.H., et al., “The calcium story and electron beam computed tomography,”Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, Fuster, V. (Ed.),Futura Publishing Co., Inc., 1996, 417-427.
Budoff, M.J., et al., “Rates of progression of coronary calcium by electron beam tomography,”Am. J. Cardiol., Jul. 1, 2000, 86, 8-11.
Caravan, P., et al., “Gadolinium(III) chelates as MRI contract agents: structure, dynamics, and applications,”Am. Chem. Soc., 1999, 99(9), 2293-2352.
Carrington, C., “Could coronary calcium screening prevent this?,”Diagnostic Imaging, Apr. 2000, 48-53.
Cerqueira, M.D., et al., “Current status of radionuclide tracer imaging of thrombi and atheroma,”Seminars in Nucl. Med., W.B. Saunders Co.,, Oct. 1999, 29(4), 339-351.
Cooper, E.S., “Prevention: the key to progress; President's address to the 65thscientific sessions of the American Heart Association,”Circulation, Apr. 1993, 87(4), 1430-1433.
Delbeke, D., “Oncological applications of FDG PET imaging,”J. Nucl. Med., Oct. 1999, 40(10), 1706-1715.
Dinsmore, R.E., et al., “Imaging techniques in carotid and peripheral vascular disease,”Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, Fuster, V. (Ed.),Futura Publishing Co., Inc., 1996, 277-289.
Doherty, T.M., et al., “Coronary calcium: the good, the bad, and the uncertain,”Am. Heart J., May 1999, 137, 806-814.
Doyle, M., et al., “Magnetic resonance coronary artery imaging,”Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, Fuster, V. (Ed.),Futura Publishing Co., Inc., 1996, 313-332.
Duncan, K., “Radiopharmaceuticals in PET imaging,”J. of Nucl. Med. Technol., 1998, 26, 228-234.
Elmaleh, D.R., et al., “Rapid noninvasive detection of experimental atherosclerotic lesions with novel99mTc-labeled diadenosine tetraphosphates,”Proc. Natl. Acad. Sci. USA, Jan. 1998, 95, 691-695.
Erbel, R., et al., “Electron-beam computed tomography for detection of early signs of coronary arteriosclerosis,”Eur. Heart J., 2000, 21, 720-732.
Farb, A., et al., “Sudden coronary death,”Circulation, 1995, 92, 1701-1709.
Fawell, S., et al., “Tat-mediated delivery of heterologous proteins into cell,”Proc. Natl. Acad. Sci. USA, Jan. 1994, 91, 664-668.
Freeman, M., et al., “Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: Lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized low density lipoprotein,”Proc. Natl. Sci. USA, Jun. 1991, 88, 4931-4935.
Fuster, V., et al., “The pathogenesis of coronary artery disease and the acute coronary syndromes,”N. Engl. J. Med., Jan. 23, 1992, Epstein, F.H. (Ed.), 326, 242-250.
Galis, Z.S., et al., “Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases,”Proc. Acad. Sci. USA, Jan. 1995, 92, 402-406.
Glover, G.D., et al., “Research directions in MR imaging,”Radiology, 1998, 207, 2
Edwards David Scott
Liu Shuang
Bristol-Myers Squibb Pharma Company
Jones Dameron L.
Woodcock & Washburn LLP
LandOfFree
Labeled macrophage scavenger receptor antagonists for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Labeled macrophage scavenger receptor antagonists for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Labeled macrophage scavenger receptor antagonists for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3517696